<DOC>
	<DOCNO>NCT01710163</DOCNO>
	<brief_summary>The purpose study determine whether Bipolar I Disorder refractory treatment Quetiapine monotherapy could well potentiate Lithium Aripiprazole . The investigator hypothesize Lithium Aripiprazole would provide similar compliance tolerability maintenance treatment .</brief_summary>
	<brief_title>Potentiation Quetiapine Treatment With Lithium Aripiprazole Bipolar 1 Nonresponders Patients</brief_title>
	<detailed_description />
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Central Nervous System Depressants</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>Clinical diagnosis Bipolar Disorder , type I , current episode ( manic/hypomanic , mixed depression ) The patient ( ) legal representative understand nature study sign Informed Consent Schizophrenia schizoaffective disorder Mental retardation Unstable clinical disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Lithium Carbonate</keyword>
	<keyword>Lithium</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Antimanic Agents</keyword>
	<keyword>Tranquilizing Agents</keyword>
	<keyword>Central Nervous System Depressants</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Sensory System Agents</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Antidepressive Agents</keyword>
</DOC>